XML 53 R37.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Significant Accounting Policies - Additional Information (Detail)
12 Months Ended
Dec. 31, 2019
USD ($)
Segment
Customer
Dec. 31, 2018
USD ($)
Dec. 31, 2017
Dec. 31, 2012
USD ($)
Significant Accounting Policies [Line Items]        
Trade receivables, credit period 30 days      
U.S. federal corporate tax rate 21.00% 21.00% 34.00%  
Number of operating segments | Segment 1      
Minimum        
Significant Accounting Policies [Line Items]        
Trade receivables, credit period 30 days      
Maximum        
Significant Accounting Policies [Line Items]        
Trade receivables, credit period 60 days      
Embedded Derivative Financial Instruments | BioPharma Debt        
Significant Accounting Policies [Line Items]        
Maximum repayment of future revenue and receivables       $ 150,000,000.0
Fair value of embedded derivative liability $ 0 $ 0    
Gain (loss) on change in fair value of derivative liabilities $ 0 $ 0    
Embedded Derivative Financial Instruments | BioPharma Debt | Minimum        
Significant Accounting Policies [Line Items]        
Derivative liability fair value assumption, coupon rate 6.00% 5.40%    
Derivative liability fair value assumptions, market yields 5.20% 6.70%    
Embedded Derivative Financial Instruments | BioPharma Debt | Maximum        
Significant Accounting Policies [Line Items]        
Derivative liability fair value assumption, coupon rate 11.50% 10.80%    
Derivative liability fair value assumptions, market yields 16.80% 15.80%    
Embedded Derivative Financial Instruments | BioPharma Debt | Measurement Input, Expected Term | Minimum        
Significant Accounting Policies [Line Items]        
Derivative liability fair value assumptions, term 1 year 10 months 24 days 1 year 3 months 18 days    
Embedded Derivative Financial Instruments | BioPharma Debt | Measurement Input, Expected Term | Maximum        
Significant Accounting Policies [Line Items]        
Derivative liability fair value assumptions, term 7 years 3 months 18 days 4 years    
Gross Product Sales | Customer Concentration Risk        
Significant Accounting Policies [Line Items]        
Number of customers | Customer 3      
Customer A | Gross Product Sales | Customer Concentration Risk        
Significant Accounting Policies [Line Items]        
Concentration risk percentage 36.00% 31.00%    
Customer A | Accounts Receivable | Customer Concentration Risk        
Significant Accounting Policies [Line Items]        
Concentration risk percentage 35.00% 26.00%    
Customer B | Gross Product Sales | Customer Concentration Risk        
Significant Accounting Policies [Line Items]        
Concentration risk percentage 29.00% 30.00%    
Customer B | Accounts Receivable | Customer Concentration Risk        
Significant Accounting Policies [Line Items]        
Concentration risk percentage 20.00% 24.00%    
Customer C | Gross Product Sales | Customer Concentration Risk        
Significant Accounting Policies [Line Items]        
Concentration risk percentage 25.00% 27.00%    
Customer C | Accounts Receivable | Customer Concentration Risk        
Significant Accounting Policies [Line Items]        
Concentration risk percentage 37.00% 39.00%    
2017 Notes        
Significant Accounting Policies [Line Items]        
Aggregate principal amount of notes $ 30,000,000.0      
Convertible senior notes, discount $ 1,200,000